Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | ceramide glucosyltransferase | 0.5227 | 0.8897 | 1 |
Giardia lamblia | Ceramide glucosyltransferase | 0.237 | 0.1604 | 0.5 |
Echinococcus granulosus | ceramide glucosyltransferase | 0.5227 | 0.8897 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.5659 | 1 | 1 |
Echinococcus multilocularis | non lysosomal glucosylceramidase | 0.4561 | 0.7197 | 0.7473 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.3913 | 0.5543 | 0.1027 |
Schistosoma mansoni | ceramide glucosyltransferase | 0.5227 | 0.8897 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.5659 | 1 | 1 |
Echinococcus granulosus | bile acid beta glucosidase | 0.4561 | 0.7197 | 0.7473 |
Loa Loa (eye worm) | ceramide glucosyltransferase | 0.5227 | 0.8897 | 0.8592 |
Echinococcus multilocularis | ceramide glucosyltransferase | 0.5227 | 0.8897 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.3913 | 0.5543 | 0.1027 |
Brugia malayi | Ceramide glucosyltransferase | 0.5227 | 0.8897 | 0.8592 |
Echinococcus granulosus | non lysosomal glucosylceramidase | 0.4561 | 0.7197 | 0.7473 |
Onchocerca volvulus | Ceramide glucosyltransferase homolog | 0.5227 | 0.8897 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.5659 | 1 | 1 |
Loa Loa (eye worm) | O-glycosyl hydrolase family 30 protein | 0.5659 | 1 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.5659 | 1 | 1 |
Schistosoma mansoni | bile acid beta-glucosidase-related | 0.4561 | 0.7197 | 0.7473 |
Loa Loa (eye worm) | hypothetical protein | 0.3079 | 0.3414 | 0.1588 |
Echinococcus multilocularis | bile acid beta glucosidase | 0.4561 | 0.7197 | 0.7473 |
Onchocerca volvulus | Glucosylceramidase homolog | 0.3713 | 0.5033 | 0.5657 |
Schistosoma mansoni | bile acid beta-glucosidase-related | 0.4561 | 0.7197 | 0.7473 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.5659 | 1 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.5659 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.